文献速递药物不良反应与药物警戒

CUSP评分:自动识别高临床效用自发报告的方法

Finding Needles in the Haystack: Clinical Utility Score for Prioritisation (CUSP), an Automated Approach for Identifying Spontaneous Reports with the Highest Clinical Utility.
PubMed 文献 · Drug Saf · 2023-08-03

研究开发并测试了自动化的临床效用优先评分(CUSP),用于辅助药物警戒专家在病例量大的情况下优先进行临床评估。在包含五个导致标签变更的药物-事件对的参考数据集上测试,关键病例的平均CUSP评分为19.7,低效用病例为17.3,但各药物-事件对的预测性能差异较大。

要点

  • CUSP是首个自动化的临床效用评分系统,旨在优先安排ICSR的临床审查。
  • 在参考数据集上,关键病例的CUSP评分分布偏向高分段。
  • 不同药物-事件对的预测能力差异显著,三个对预测关键病例能力较高。

核心结论

  • CUSP是首个成功开发的自动化临床效用评分系统,可支持ICSR的优先临床审查。

研究设计与样本

  • 在包含五个导致标签变更的药物-事件对的个体病例安全性报告参考数据集上测试CUSP方法。

主要发现

  • 关键病例的平均CUSP评分为19.7(中位数21,范围7-27),低效用病例为17.3(中位数19,范围4-27)。
  • 关键病例的CUSP分布相比所有病例偏向更高分数范围。
  • 每个药物-事件对的整体性能差异很大,三个对预测关键病例能力较高(平均CUSP 22.8,范围22.5-23.0),两个较低(平均CUSP 17.6,范围14.5-20.7)。

临床怎么用

  • CUSP可帮助药物警戒专家在病例量大时优先进行临床评估,提高病例系列审查的快速性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Spontaneous reporting of adverse events has increased steadily over the past decades, and although this trend has contributed to improving post-marketing surveillance pharmacovigilance activities, the consequent amount of data generated is challenging to manually review during assessment, with each individual report requiring review by pharmacovigilance experts. This highlights a clear need for alternative or complementary methodologies to help prioritise review. OBJECTIVE: Here, we aimed to develop and test an automated methodology, the Clinical Utility Score for Prioritisation (CUSP), to assist pharmacovigilance experts in prioritising clinical assessment of safety data to improve the rapidity of case series review when case volumes are large. METHODS: The CUSP method was tested on a reference dataset of individual case safety reports (ICSRs) associated to five drug-event pairs that led to labelling changes. The selected drug-event pairs were of varying characteristics across the portfolio of GSK's products. RESULTS: The mean CUSP score for 'key cases' and 'cases of low utility' was 19.7 (median: 21; range: 7-27) and 17.3 (median: 19; range: 4-27), respectively. CUSP distribution for 'key cases' were skewed toward the higher range of scores compared with 'all cases'. The overall performance across each individual drug-event pair varied considerably, showing higher predictive power for 'key cases' for three of the drug-event pairs (average CUSP between these three: 22.8; range: 22.5-23.0) and lesser power for the remaining two (average CUSP between these two: 17.6; range: 14.5-20.7). CONCLUSION: Although several tools have been developed to assess ICSR completeness and regulatory utility, this is the first attempt to successfully develop an automated clinical utility scoring system that can support the prioritisation of ICSRs for clinical review.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Kara V, Powell G, Mahaux O, et al. Finding Needles in the Haystack: Clinical Utility Score for Prioritisation (CUSP), an Automated Approach for Identifying Spontaneous Reports with the Highest Clinical Utility. Drug Saf. 2023. PMID: 37535258. doi:10.1007/s40264-023-01327-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。